| Click on "►" to expand:|
 BRAND NAMES
 MECHANISM OF ACTION
Blood clotting can be a problem when blood flow is disturbed in any way. Bivalirudin is an anticoagulant, which means that it prevents the blood from clotting. Bivalirudin, is a synthetic substance derived from hirudin, the anticoagulant substance produced by leeches. It is a specific and reversible direct thrombin inhibitor (DTI).
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently crosslinked framework that stabilises the thrombus. Thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. Bivalirudin inhibits each of these thrombin effects
Using Bivalirudin greatly reduces the risk of a blood clot forming. This can improve the effectiveness of Percutaneous coronary intervention (PCI) and help to maintain the flow of blood to the heart in patients with angina or myocardial infarction.
Bivalirudin is indicated for use as an anticoagulant in patients:
- With unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
- Undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI).
- With, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI.
Bivalirudin is intended for use with aspirin.
- Active major bleeding
- Hypersensitivity to bivalirudin or any product components
- Increased major bleeding risk with concomitant use of Heparin, warfarin, thrombolytics, or glycoprotein IIb/IIIa inhibitors (GPIs)
 PREGNANCY AND LACTATION
 SIDE EFFECTS
The most common side effect with Bivalirudin (seen in more than 1 patient in 10) is minor bleeding. Other adverse reactions (incidence >0.5%) were headache, thrombocytopenia and fever
 RELATED LINKS